comprehensive -WSS

comprehensive

author：knowledge 2025-09-28 00:49:06 - browse：64

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： How to convince healthy people to buy insurance

WSS

Key Senate panel to consider PBM, drug pricing reform package

Kidney transplant patients stopped immunosuppressants in trial

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

5 takeaways from STAT's examination of Zynex Medical

Live blog: Hearing on CRISPR

Readers discuss the intersection of pregnancy and addiction

hotspot

comprehensive

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Study: Why relieving medical debt did not improve financial outcomes

Jerome Adams on the need for new antivirals for Covid

Humans aren't the only ones with an imagination. Rats have it too

Drug repurposing or repositioning? The language matters

Teladoc has a new CEO, but challenges remain the same

ChatGPT in medicine: STAT answers readers' burning questions

How faith leaders like me can help address America's obesity epidemic

In Memoriam: Notable people who died in 2023

Study: Why relieving medical debt did not improve financial outcomes

focus

Kidney transplant patients stopped immunosuppressants in trial

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Prime Medicine says its gene editing passes test in monkeys

What is microchimerism and how does it affect maternal health?

DeepMind touts AlphaFold's new skills as protein folding AI models face off

5 takeaways from STAT's examination of Zynex Medical

leisure time

hotspot

focus

leisure time